OSE-127/S95011
Ulcerative Colitis
Key Facts
About OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated, clinical-stage biotechnology company focused on developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation. Its core strategy is driven by three proprietary technology platforms designed to precisely modulate the immune system. The company's most significant near-term catalyst is the Phase 3 ARTEMIA trial for Tedopi® in non-small cell lung cancer, which has received two positive IDMC recommendations. OSE aims to build value through a diversified pipeline and strategic partnerships.
View full company profileAbout OSE Immunotherapeutics
OSE Immunotherapeutics is an integrated, clinical-stage biotechnology company focused on developing first-in-class immunotherapies for immuno-oncology and immuno-inflammation. Its core strategy is driven by three proprietary technology platforms designed to precisely modulate the immune system. The company's most significant near-term catalyst is the Phase 3 ARTEMIA trial for Tedopi® in non-small cell lung cancer, which has received two positive IDMC recommendations. OSE aims to build value through a diversified pipeline and strategic partnerships.
View full company profileTherapeutic Areas
Other Ulcerative Colitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PALI-2108 | Palisade Bio | Phase 2 |
| ALTB-268 | AltruBio | Phase IIa |
| AIM-HI-UC | PathAI | Clinical Trials |
| Patient Stratification in Ulcerative Colitis | Enable Medicine | Research |
| Mesalazine (Lifecycle Management) | Dr. Falk Pharma | Approved/Phase 3 |
| AhR Agonist Program | Azora Therapeutics | Phase 1b |
| R-3750 | Virtici | Phase 1 |
| GPR35 Inhibitor | ThirtyFiveBio | Preclinical |
| BEN-8744 | BenevolentAI | Phase 1b |
| BT-600 | Biora Therapeutics | Phase 1 |
| Asacol® (mesalazine) | Tillotts Pharma | Approved |
| MB310 | Microbiotica | Phase 1b |